智通财经APP数据显示，截止3月11日收盘，有78只股票创52周新高，其中位元堂(00897)、乐思集团(02540)、博雅互动(00434)创高率位于前3位，分别为198.85%、65.00%、30.64%。另外有54只股票创52周新低，其中中国供应链产业(03708)、呷哺呷哺(00520)、朸濬国际(01355)创低率位于前三位，分别为-41.86%、-13.45%、-10.71%。 52周新高排行 股票名称 收盘价 最高价 创高率 位元堂(00897) 0.226 0.260 198.85% 乐思集团(02540) 2.500 2.640 65.00% 博雅互动(00434) 2.260 2.260 30.64% 光尚文化控股(08082) 0.041 0.042 13.51% 中电华大科技(00085) 1.790 1.840 10.84% 长久股份(06959) 24.500 24.450 10.63% 怡俊集团控股(02442) 1.960 2.360 9.77% TS WONDERS(01767) 0.220 0.220 8.91% 华营建筑(0158 ...

Revenue and Profit Performance - Revenue for the six months ended 30 September 2023 increased to HK$678,804,000, up from HK$606,127,000 in the same period last year, representing a growth of approximately 12%[18] - Gross profit for the period was HK$324,027,000, compared to HK$268,189,000 in the previous year, reflecting a 20.8% increase[18] - Profit before tax for the six months ended 30 September 2023 was HK$38,429,000, a significant improvement from a loss of HK$19,023,000 in the same period last year[18] - Profit attributable to owners of the parent was HK$3.549 million, a turnaround from a loss of HK$53.385 million in the previous year[25] - Basic and diluted earnings per share attributable to ordinary equity holders of the parent were HK0.30 cents, compared to a loss of HK4.35 cents in the same period last year[26] - Revenue for the period reached 2,097,109 units[156] - Profit for the period was 3,549 units[170] Share Repurchase and Issuance - The company repurchased 33,540,000 shares at a total cost of HK$14,727,600 during July 2023, with the highest purchase price per share at HK$0.45 and the lowest at HK$0.425[10] - The total number of shares in issue as of 30 September 2023 was 1,171,102,888[10] - Rich Time, WOE, and Wang On each hold 810,322,940 shares, representing 69.19% of the company's shares[34] - Mr. Tang holds a 50.67% interest in Wang On, which indirectly owns Rich Time and WOE, both holding 810,322,940 shares in the company[36] - Mr. Tang Ching Ho holds 7,320,095,747 shares in CAP, representing approximately 73.54% of CAP's total issued share capital[87] - Mr. Tang Ching Ho is also interested in 810,322,940 shares of the Company held by Rich Time Strategy Limited, with an approximate 50.67% interest[88] Share Option Schemes - The 2013 Share Option Scheme expired on 21 August 2023, and a new 2023 Share Option Scheme was adopted on 22 August 2023, effective for 10 years[40] - The 2023 Share Option Scheme allows the company to grant options to employees, directors, and associates as incentives, with a maximum issuance limit of 10% of the company's issued shares[40] - Any grant of options resulting in shares issued or to be issued exceeding 1% of the company's total shares within a 12-month period requires separate shareholder approval, with the participant and close associates abstaining from voting[42] - Share options granted to directors, chief executives, or substantial shareholders must be approved by independent non-executive directors (INEDs), excluding any INED who is the grantee[42] - Grants to substantial shareholders or INEDs resulting in shares exceeding 0.1% of the company's total shares within 12 months require shareholder approval via a poll, with the grantee and associates abstaining from voting[42] - The exercise period for options is determined by the Board but must not exceed 10 years from the grant date[42] - The minimum holding period before options can be exercised is generally not less than 12 months, with a vesting period that may be shortened under certain circumstances to encourage exceptional performance[42] - The 2023 Share Option Scheme is valid for 10 years starting from August 22, 2023, with no further options to be granted after this period, though existing options remain exercisable[42] - The exercise price for options must not be less than the highest of: (i) the closing price on the grant date, (ii) the average closing price for the 5 business days preceding the grant date, or (iii) the nominal value of the company's shares[42] - No share options were granted, exercised, cancelled, or lapsed under the 2013 and 2023 Schemes during the period, with 117,110,288 share options available for grant as of 30 September 2023[45] - The CAP 2022 Scheme, effective from 26 August 2022, allows the CAP Board to grant share options to eligible participants, with a validity period of 10 years until 25 August 2032[45] - The number of share options granted to any CAP Participant in any 12-month period cannot exceed 1% of the issued CAP Shares without prior shareholder approval[48] - Share options granted to substantial shareholders or independent non-executive directors exceeding 0.1% of issued CAP Shares and HK$5,000,000 in value require prior shareholder approval[48] - The CAP Board may refresh the share option limit to 10% of the total issued CAP Shares, subject to shareholder approval, with a cap of 30% for all outstanding options[49] - As of 30 September 2023, 50,000,000 share options were outstanding for CAP Director Leung Sui Wah, Raymond, with an exercise price of HK$0.118 per share[53] - Other employees had 126,000,000 share options outstanding as of 30 September 2023, down from 161,000,000 due to 35,000,000 lapsed options[53] - The total outstanding share options under the CAP 2012 Scheme decreased from 211,000,000 to 176,000,000 during the period, primarily due to lapsed options[53] - 35,000,000 share options lapsed under the CAP 2012 Scheme, leaving 176,000,000 shares available for issue, representing approximately 1.77% of the existing issued share capital of CAP[56] - No share options were granted, exercised, canceled, or lapsed under the CAP 2022 Scheme, with 995,306,782 share options remaining available for grant as of 30 September 2023[56] Asset and Liability Changes - Total non-current assets decreased to HK$4.057 billion from HK$4.311 billion as of 31 March 2023[27] - Total current assets decreased to HK$2.526 billion from HK$2.702 billion as of 31 March 2023[27] - Net current assets were HK$910.085 million, down from HK$1.045 billion as of 31 March 2023[27] - Trade receivables decreased to HK$66.566 million from HK$68.028 million as of 31 March 2023[27] - Cash and cash equivalents decreased to HK$456 million from HK$525.869 million as of 31 March 2023[27] - Trade payables increased to HK$125.164 million from HK$79.489 million as of 31 March 2023[27] - Other payables and accruals decreased to HK$640.713 million from HK$690.388 million as of 31 March 2023[27] - Total assets less current liabilities decreased from HK$5,356,627,000 to HK$4,968,002,000 as of 30 September 2023[62] - Non-current liabilities decreased from HK$1,668,243,000 to HK$1,482,266,000, primarily due to reductions in unsecured notes and interest-bearing bank borrowings[62] - Net assets decreased from HK$3,688,384,000 to HK$3,485,736,000, with equity attributable to owners of the parent declining from HK$2,349,191,000 to HK$2,225,827,000[62] - Total assets amounted to 2,349,191 units[166] Comprehensive Loss and Other Financial Metrics - Total comprehensive loss for the period was HK$189.922 million, compared to HK$420.356 million in the same period last year, showing a significant improvement[22][25] - Net loss for the period was (27,150) units[157] - Other comprehensive loss for the period was (10,076) units[185] - Changes in fair value resulted in a loss of (23,420) units[186] - Reversal of impairment losses on financial assets was (13,344) units[191] - Reclassification adjustment for gains/losses included in profit or loss was (93) units[200] Corporate Governance - The Company deviated from code provision C.2.1 of the Corporate Governance Code, with Mr. Tang Ching Ho serving as both chairman and managing director[59] - The Company maintains a high standard of corporate governance, emphasizing transparency, accountability, integrity, and independence[60] - The Board comprises three executive Directors and four independent non-executive Directors, ensuring a balance of skills and experience for the Group's development[59]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位 元 堂 藥 業 控 股 有 限公 司 *） （於百慕達註冊成立之有限公司） （股份代號：897） 截至二零二三年九月三十日止六個月之中期業績公佈 中期財務摘要 截至九月三十日止六個月 二零二三年 二零二二年 變動 百萬港元 （未經審核） （未經審核） 收益 678.8 606.1 12.0% 毛利 324.0 268.2 20.8% 母公司擁有人應佔溢利╱（虧損） 3.5 (53.4) 106.6% 每股盈利╱（虧損）（港仙） — 基本及攤薄 0.30 (4.35) 4.65 於 於 二零二三年 二零二三年 ...

Sales Performance and Market Position - Wai Yuen Tong has maintained its position as the top-selling product in the cough remedy category for nine consecutive years, based on sales value and volume in Hong Kong[14]. - Wai Yuen Tong's Hou Tsao Powder has been recognized for its sales performance, reinforcing the brand's market leadership[14]. - The flagship products include "Angong Niuhuang Wan" series, "Young Yum Pill," and "Hou Tsao Powder," with the latter ranked first in sales for 9 consecutive years in Hong Kong[28]. - The Group's flagship brand "Madame Pearl's" achieved the Hong Kong cough syrup sales champion for 12 consecutive years, supported by strategic sales and marketing efforts[58]. - The revenue of "Pearl's" Mosquitout product range reported satisfactory growth over the previous year, establishing leadership in the mosquito repellent product category in Hong Kong[59]. Commitment to Traditional Chinese Medicine (TCM) - The company reported a commitment to promoting Traditional Chinese Medicine (TCM) globally, emphasizing the importance of TCM in socio-economic development and healthcare services[22]. - The State Council of China has outlined future development priorities for TCM, indicating strong governmental support for the industry[22]. - Wai Yuen Tong aims to establish higher quality standards in the TCM industry while providing comprehensive pharmaceutical products and services[23]. - The company continues to focus on the integration of traditional practices with modern healthcare needs, aligning with national health policies[22]. - The company is positioned to leverage the growing demand for TCM services due to an aging population and the booming healthcare services industry in China[22]. Financial Performance - Total revenue for the financial year ended March 31, 2023, decreased by approximately 7.5% to approximately HK$1,286.4 million, primarily due to a decrease in property sales in agricultural produce exchange markets[46]. - The Group recorded a loss attributable to owners of the parent of approximately HK$20.5 million, a significant reduction from a loss of approximately HK$108.9 million in the previous year[47]. - Revenue from Chinese pharmaceutical and health food products increased to approximately HK$635.0 million, representing a growth of approximately 23.9% from the previous year[56]. - The total revenue of traditional Chinese medicine and health food products increased to approximately HK$635 million, representing a growth of about 23.9% compared to the previous year[60]. - The total revenue of Western pharmaceutical and health food products grew by 100.1% over the same period last year[64]. Business Expansion and Operations - As of March 31, 2023, the Group operated over 100 stores across Mainland China, Hong Kong, and Macau, with more than 80 Chinese medicine practitioners in Hong Kong[28]. - During the review year, the Group opened 9 new stores in Hong Kong and Macau, particularly in residential districts, indicating a growing demand for Chinese medicine clinic services[27]. - The Group launched new products across five major categories of Chinese medicine, enhancing product diversity and selection[28]. - The Group's business model leverages franchised stores for rapid expansion in the Chinese medicine sector[28]. - The Group has actively developed e-commerce business channels, distributing products through its own online platform and selected third-party platforms[63]. Legal Matters and Corporate Governance - The group continues to be the legal and beneficial owner of Baisazhou Agricultural, as confirmed by multiple court rulings[149][156]. - On April 20, 2023, the court ruled that Ms. Wang and Tian Jiu must pay damages to the group amounting to HK$567,037,325.74, plus interest from January 18, 2021[157]. - The group has been involved in multiple civil litigations since 2011 related to the Baisazhou acquisition, with various court decisions upholding its ownership[144][153]. - The Supreme People's Court dismissed the appeal from Ms. Wang and Tian Jiu regarding the December 23, 2019 judgment, reaffirming the group's ownership[153][158]. - The group has faced allegations of forged documentation related to the Baisazhou acquisition, which have been dismissed by the courts[145][152]. Sustainability and Corporate Social Responsibility - The company has received recognition as a "Caring Company" for over 10 years, reflecting its commitment to social responsibility[15]. - The Group's commitment to sustainability includes the installation of solar panels at the Yuen Long Factory to reduce carbon emissions[32]. - The Group's agricultural produce exchange markets have maintained health and hygiene measures to adapt to the post-pandemic environment[189]. Management and Employee Relations - CAP employed 1,941 staff as of March 31, 2023, an increase from 1,872 in 2022, with approximately 35.4% located in Hong Kong and Macau[172]. - The company provides various employee benefits, including medical and retirement benefits, and structured training programs[172]. - CAP recognizes employees as key contributors to its success and strives to provide a safe workplace[172]. - CAP has adopted a share option scheme in August 2022 to incentivize eligible participants and enhance the company's value[172]. Market Outlook and Strategic Initiatives - The expected faster growth of Mainland China's economy and the lifting of cross-boundary restrictions are anticipated to support Hong Kong's exports[182]. - Wai Yuen Tong aims to increase market share by opening self-operated and franchised retail outlets in the PRC, Hong Kong, and Macau[183]. - The CAP Group plans to build a nationwide agricultural produce exchange network leveraging its industry-leading position and advanced management systems[184]. - The Central Government of China has prioritized agricultural development, promoting investments in agricultural produce markets and improving logistics infrastructure[190]. - The CAP Group is adopting an "asset light" strategy to expand operations in the PRC and is exploring online platform development to leverage technology advancements[191].

Financial Performance - For the six months ended September 30, 2022, total revenue decreased by approximately 7.6% to approximately HK$606.1 million, primarily due to decreased sales performance in the management and sale of properties in agricultural produce exchange markets[15]. - The Group recorded a loss attributable to owners of the parent amounting to approximately HK$53.4 million, compared to a profit of approximately HK$14.1 million for the same period in 2021[16]. - The loss was mainly due to a decrease in fair value gains on investment properties, impairment losses on property, plant and equipment, and a decrease in revenue from property sales in agricultural produce exchange markets in the PRC[16]. - Revenue for the six months ended 30 September 2022 was HK$606,127,000, a decrease from HK$656,082,000 in the same period of 2021, representing a decline of approximately 7.6%[180]. - Gross profit for the same period was HK$268,189,000, down from HK$275,213,000, reflecting a decrease of about 2.4%[180]. - The Company reported a loss before tax of HK$19,023,000 for the six months ended 30 September 2022, compared to a profit of HK$54,289,000 in the prior year[180]. - The profit for the period was a loss of HK$35,643,000, contrasting with a profit of HK$35,320,000 in the same period of 2021[180]. - The company reported a total comprehensive loss attributable to owners of the parent of HK$239,983,000 for the six months ended September 30, 2022, compared to a comprehensive income of HK$81,851,000 in the same period of 2021[187]. - The profit attributable to owners of the parent was a loss of HK$53,385,000 for the six months ended September 30, 2022, compared to a profit of HK$14,109,000 in the same period of 2021[187]. Revenue Sources - The revenue of Chinese pharmaceutical and health food products business recorded a healthy growth of approximately 11.1% compared to the same period in 2021[22]. - The total revenue of Western pharmaceutical and personal care products business delivered a growth of approximately 80.6% over the corresponding period in 2021[24]. - The decline in revenue from property sales in the PRC was attributed to the performance of the Company's 53.37%-owned subsidiary, China Agri-Products Exchange Limited[16]. - CAP managed 11 agricultural produce exchange markets across five provinces in the PRC, generating revenue of approximately HK$303.6 million, down from approximately HK$393.6 million in the same period of 2021[31]. - Revenue from operating agricultural produce exchange markets was approximately HK$195.4 million, compared to approximately HK$203.0 million in the previous year[31]. - Revenue from the sale of properties was approximately HK$108.2 million, a decline from approximately HK$190.6 million in the same period of 2021[31]. Operational Developments - The Group has launched three Chinese specialists centers in Central, Causeway Bay, and Jordan to provide specialized solutions for patients with special medical needs[24]. - The Group plans to introduce nutritious soft meals for the elderly and an advanced disinfectant range under the brand name "Pearl's" in the coming year[24]. - The Group has been actively deploying resources to establish e-commerce channels, including distribution through its own online platform and selected third-party platforms[27]. - The Group expanded its property portfolio by subdividing a property in Mongkok, increasing owned properties from 13 to 14[29][33]. - The Group aims to improve the performance of the existing retail outlet portfolio to counteract the negative impact of the current uncertain business environment[24]. - The Group's efforts in strategic sales and marketing activities have contributed to its market leadership in the mosquito repellent product market in Hong Kong[24]. Financial Position - As of September 30, 2022, the Group's total assets were approximately HK$6,914.2 million, down from approximately HK$7,597.7 million as of March 31, 2022[43]. - The Group's total interest-bearing debts amounted to approximately HK$1,752.8 million as of September 30, 2022, an increase from approximately HK$1,681.2 million as of March 31, 2022[47]. - The current ratio was approximately 1.7 as of September 30, 2022, compared to approximately 1.5 as of March 31, 2022[50]. - The gearing ratio increased to approximately 51.1% as of September 30, 2022, up from approximately 45.3% as of March 31, 2022[50]. - The Group held financial assets at fair value through other comprehensive income of approximately HK$143.7 million and financial assets at fair value through profit or loss of approximately HK$46.0 million as of September 30, 2022[55]. - The Group's total non-current assets decreased to HK$4,315,163,000 as of September 30, 2022, from HK$4,709,007,000 as of March 31, 2022[190]. - Current assets totaled HK$2,599,038,000 as of September 30, 2022, down from HK$2,888,706,000 as of March 31, 2022[190]. - The company's cash and cash equivalents increased to HK$584,962,000 as of September 30, 2022, compared to HK$510,146,000 as of March 31, 2022[190]. Shareholder Information - The CAP Group owns approximately 73.54% of CAP's total issued share capital, amounting to 7,320,095,747 shares[124]. - Mr. Tang Ching Ho holds 67.26% of the company's total issued share capital, with 810,322,940 shares[117]. - The shareholding structure indicates that Mr. Tang and his associates have significant control over the Company through various subsidiaries[142]. - The Company has not granted any rights to acquire shares or debentures to its Directors or chief executives during the reporting period[137]. - The total number of shares held by major shareholders reflects a concentrated ownership structure, with Rich Time and its affiliates holding a substantial portion[139]. Corporate Governance - The company emphasizes maintaining a high standard of corporate governance with a focus on transparency, accountability, integrity, and independence[155]. - The board comprises three executive directors and four independent non-executive directors, ensuring a balance of skills and experience[154]. - The Company has established an Audit Committee to oversee financial reporting, internal controls, and risk management[177]. - The company does not propose to comply with code provision C.2.1 of the Corporate Governance Code for the time being but will continue to review such deviation[154]. Legal Matters - Since 2011, CAP Group has been involved in multiple civil proceedings in the PRC and Hong Kong regarding the Baisazhou Acquisition[82]. - The Hubei Court dismissed Ms. Wang and Tian Jiu's counterclaim for the return of CAP Group's 90% interest in Baisazhou Agricultural in December 2019[90]. - The Supreme People's Court upheld the Hubei Court's decision on 29 March 2021, confirming CAP Group's ownership of Baisazhou Agricultural[88]. - The former director of Baisazhou Agricultural was found guilty of misappropriating funds amounting to RMB 40.0 million and was sentenced to five years in prison[95]. Market Strategy - The Group plans to expand its market share by opening more retail outlets in the PRC, Hong Kong, and Macau, leveraging the development of the Guangdong-Hong Kong-Macau Greater Bay Area[106]. - The Group aims to launch more unique health supplements under the "Madame Pearl's" brand to meet market needs[107]. - The CAP Group will continue to build a nationwide agricultural produce exchange network, leveraging its leading industry position and advanced management systems[108]. - The Group's strategy includes enhancing cross-border e-commerce to reach consumers in the Greater Bay Area and the Asia Pacific Region[107]. - The CAP Group is pursuing an "asset light" strategy to expand operations in the PRC, focusing on partnerships and electronic platform development to leverage technology advancements promoted by the government[112].

Company Overview - Wai Yuen Tong Medicine Holdings Limited has maintained a strong reputation in providing Chinese and Western pharmaceutical products and services for over 125 years[19]. - The company has been recognized as a "Caring Company" for over 10 years by the Hong Kong Council of Social Service[17]. - The annual report for the year ended March 31, 2022, highlights the company's commitment to health and wellness in the community[22]. - The company continues to focus on excellence in both Chinese and Western medicine, as well as outpatient clinic services[19]. - The company aims to leverage the synergy between traditional Chinese medicine and Western pharmaceuticals to enhance its market position[68]. Product Performance - The company reported a significant achievement with its Hou Tsao Powder, ranking 1st in sales value and volume for 8 consecutive years in Hong Kong[14]. - Wai Yuen Tong's Madame Pearl's Cough Syrup has been the sales champion for 12 consecutive years in Hong Kong[17]. - The sales performance of Western pharmaceutical and personal care products increased by 61% compared to the previous year[49]. - The Group's flagship product, Hou Tsao Powder, ranked first in sales value and volume for 8 consecutive years in Hong Kong[37]. - The key brand "Madame Pearl's" has been the sales champion for cough syrup in Hong Kong for 12 consecutive years, with a target to achieve an annual production capacity of 10 million bottles of cough syrup[83]. Market Expansion and Development - Wai Yuen Tong aims to expand its market reach and enhance its product development strategies moving forward[19]. - The Group opened 4 new retail stores in local districts, increasing the total to 63 stores providing one-stop Chinese medicine healthcare services as of March 31, 2022[38]. - The first "Wai Yuen Tong Chinese Medicine Specialist Center" was launched, with two more expected to open by the end of 2022, enhancing access to traditional Chinese medicine services[39]. - The Group plans to expand the production capacity of cough syrup to 10 million bottles annually at the Yuen Long Factory[49]. - The Group's flagship stores on Tmall.com and JD.com were established to serve domestic consumers in Mainland China[45]. Community and Health Initiatives - The Chairman expressed gratitude for the dedication of all colleagues during a challenging year, emphasizing the importance of tradition and community health[19]. - The Group actively cooperated with the Hong Kong government in pandemic prevention, providing remote diagnosis and treatment services during the COVID-19 outbreak[32]. - The Group donated 7,000 tablets of Angong Niuhuang Wan and 100,000 bags of flu tea to support community health during the pandemic[53]. - The Group's Angong Niuhuang Wan was included in the National Health Commission's treatment protocol for critically ill COVID-19 patients[37]. Financial Performance - Total revenue for the financial year ended March 31, 2022, increased by approximately 25.5% to approximately HK$1,391.4 million, driven by growth in the production and sale of Chinese and Western pharmaceutical and health food products[70]. - The loss attributable to owners decreased to approximately HK$108.9 million from approximately HK$376.0 million in the previous year, primarily due to the absence of a significant loss on disposal of an investment recorded in the prior year[71]. - Revenue from Chinese pharmaceutical and health food products rose to approximately HK$512.6 million, reflecting a growth of approximately 13.1% compared to the previous year[74]. - The Group's retail store services saw a significant increase in demand during the Omicron variant outbreak, particularly in residential areas[41]. - The Group's sales of Western medicine and personal care products increased significantly by 61% compared to the previous year[51]. Legal and Regulatory Matters - CAP continues to be the legal and beneficial owner of Baisazhou Agricultural following the dismissal of the counterclaim by Ms. Wang and Tian Jiu[200]. - CAP is seeking legal advice for the recovery of the balance of the damages awarded to it[200]. - The court order from 2012 prevented CAP from making payments under the instruments until the final determination of the proceedings[200]. - The judgement from the Jianghan Court was delivered on November 19, 2021, regarding the misappropriation case[200]. - CAP's litigation efforts highlight ongoing legal challenges related to its acquisition activities[200]. Environmental Initiatives - The Group plans to install solar panels at the Yuen Long Factory in 2022 to reduce carbon emissions, aligning with the government's carbon neutrality target by 2050[24]. Economic Context - Hong Kong's economy grew by 6.4% in 2021, the highest growth rate since 2010, but remained approximately 2% below the 2018 level[29]. - The overall economy of Hong Kong grew by 6.4% in 2021, despite challenges posed by the Omicron variant and the fifth wave of COVID-19[73]. - The economic recovery in Hong Kong remains uneven, with sectors like import and export performing well, while inbound tourism is still largely inactive[73].

Financial Performance - For the six months ended September 30, 2021, the Group recorded a revenue increase of approximately 28.8% to approximately HK$656.1 million, compared to approximately HK$509.5 million in the same period of 2020[11]. - The Group recorded a profit attributable to owners of the parent amounting to approximately HK$14.1 million, a significant recovery from a loss of approximately HK$226.9 million in the same period of 2020[12]. - The profit increase was mainly due to the absence of a HK$209.0 million impairment recorded in the previous year and the overall revenue growth[12]. - Revenue from the production and sale of Chinese pharmaceutical and health food products increased by approximately 13.5% to approximately HK$239.9 million, while revenue from Western pharmaceutical and health food products increased by approximately 6.5% to approximately HK$18.3 million[11]. - Revenue from the management and sale of properties in agricultural produce exchange markets in the PRC increased by approximately 42.0% to approximately HK$393.6 million[11]. - Total comprehensive income for the period was HK$97,703,000, a turnaround from a loss of HK$30,561,000 in the same period of 2020[174]. - The profit for the period attributable to owners of the parent was HK$14,109,000, compared to a loss of HK$226,920,000 in the previous year[178]. - Gross profit for the period was HK$275,213,000, compared to HK$172,584,000 in the previous year, reflecting a gross margin improvement[171]. Economic Environment - The economic recovery in the PRC, Hong Kong, and Macau contributed to the improved financial performance, as strict anti-pandemic measures brought COVID-19 under control[11]. - The Hong Kong economy is on a recovery track with real GDP continuing to grow compared to last year, supported by improving global economic conditions and a decrease in local COVID-19 cases[18]. - The total employment rate has gradually improved, indicating a strengthening labor market, which is expected to align with the pace of economic recovery[18]. - The Consumption Voucher Scheme (CVS) is anticipated to continue supporting consumption-related activities in the near term, contributing to consumer sentiment[18]. - The government is enhancing vaccination measures and discussing border reopening with the central government to boost the economy, particularly in tourism and retail sectors[18]. Strategic Focus and Market Expansion - The Group's strategic focus on Chinese and Western pharmaceutical products has shown positive results, reflecting a growing market demand[11]. - The Group continues to explore opportunities for market expansion and new product development in response to changing consumer needs[11]. - The Group plans to expand its market share by opening retail outlets in the PRC, Hong Kong, and Macau, leveraging the Guangdong-Hong Kong-Macau Greater Bay Area policy for business development[105]. - The Group is focusing on branding efforts to strengthen customer loyalty for its "Madame Pearl's" and "Pearl's" product lines[20]. - The Group continues to invest in research and development for core medical solutions targeting institutional clients, local clinics, and medical groups[20]. Investment and Financial Strategy - The Group's investment strategy remains prudent, with a focus on long-term holdings aimed at generating stable income[57]. - The Group's treasury policy aims to ensure adequate financial resources for business growth while managing financial risks, including currency and interest rate risks[68]. - The Group intends to closely monitor market changes and adjust its investment portfolio as necessary to align with its strategic goals[57]. - The Group is adopting an "asset light" strategy to expand operations in the PRC, confident that this approach will yield long-term benefits for shareholders[110]. Employee and Corporate Governance - As of September 30, 2021, the Group employed 1,825 employees, with approximately 33.2% located in Hong Kong and Macau[97]. - The Group provides discretionary bonuses and share options based on performance, alongside regular remuneration[97]. - The Company has complied with the Corporate Governance Code throughout the six months ended September 30, 2021, except for a deviation regarding the role of the chairman and managing director[153]. - The Company emphasizes maintaining high standards of corporate governance with a focus on transparency, accountability, integrity, and independence[154]. Share Capital and Ownership - As of September 30, 2021, Mr. Tang Ching Ho holds 810,322,940 shares, representing approximately 65.79% of the company's total issued share capital[116]. - The total issued share capital of the company is 11,400,000,000 shares[130]. - The company is directly wholly-owned by Loyal Fame International Limited, which is owned by Mr. Tang[129]. - The 2013 Share Option Scheme allows share options to be granted to participants for a consideration of HK$1.00 per lot, which must be accepted within 30 days from the offer date[145].

0 艺元堂 Wai Yuen Tong Medicine Holdings Limited 位 元 堂 藥 業 控 股 有 限 公 司 Incorporated in Bermuda with limited liability 於百慕遴註冊成立之有限公司 Stock Code 股份代號: 897 Annual Repor 2 Corporate Information 公司資料 85 Independent Auditor's Report 獨立核數師報告 95 Consolidated Statement of Profit or Loss and Other Comprehensive Income 綜合損益及其他全面收益表 4 Awards 獎項 6 Chairman's Statement 主席報告 98 Consolidated Statement of Financial Position 綜合財務狀況表 14 Management Discussion and Analysis 管理層討論及分析 100 Consolidated Statement of Changes in Equity 綜 ...

Financial Performance - The company reported a significant decline in revenue due to market challenges, with specific figures not provided in the extracted content [12]. - For the six months ended 30 September 2020, the Group recorded revenue of HK$509.5 million, an increase of 80.9% compared to HK$281.6 million in the same period of 2019 [16]. - Revenue from Traditional Chinese Medicine and health food products decreased by 4.9% to HK$211.4 million, down from HK$222.3 million in 2019 [16]. - Revenue from Western pharmaceutical and health food products dropped by 68.5% to HK$17.1 million, compared to HK$54.2 million in 2019 [27]. - The Group recorded a loss attributable to owners of the parent amounting to HK$233.2 million, compared to a profit of HK$32.2 million in 2019 [16]. - The Group reported a loss before tax of HK$212,682,000 for the six months ended September 30, 2020, compared to a profit of HK$32,559,000 in 2019 [142]. - Profit attributable to owners of the parent was a loss of HK$233,191,000, contrasting with a profit of HK$32,213,000 in the previous year [149]. - Total comprehensive loss for the period was HK$42,311,000, compared to a comprehensive income of HK$12,838,000 in 2019 [146]. - Basic and diluted loss per share attributable to ordinary equity holders of the parent was HK(18.93) cents, compared to HK2.62 cents in 2019 [149]. Market Strategy and Outlook - Future outlook remains cautious as the company navigates ongoing market uncertainties and competition [12]. - The company is focusing on enhancing its product offerings and exploring new market opportunities to drive growth [12]. - The company aims to expand its market presence, particularly in regions with growth potential, although specific strategies were not outlined [12]. - Overall, the company is committed to adapting its strategies in response to evolving market conditions [12]. - The Group aims to explore new product development and sales platforms to adapt to changing market conditions [82]. - The Group plans to enhance its distribution network by penetrating more local communities and diversifying its product range to meet customer needs, while promoting scientific development in Chinese Medicine regulation [91]. Cost Management and Profitability - Management emphasizes the importance of cost control measures to maintain profitability during challenging times [12]. - Selling and distribution expenses were reduced to HK$81,547,000 from HK$114,001,000, a decrease of 28% [142]. - Administrative expenses increased significantly to HK$113,334,000 from HK$66,664,000, marking a 70% rise [142]. Investments and Acquisitions - The company is evaluating potential mergers and acquisitions to strengthen its market position, although no specific targets were disclosed [12]. - The Group's acquisition of 53.37% equity interests in China Agri-Products Exchange Limited contributed HK$277.2 million in revenue for the Period [16]. - The Group continues to invest in research and development for core medical solutions targeting institutional clients and local clinics [31]. Financial Position and Assets - As of September 30, 2020, the Group's total assets were HK$7,931.2 million, an increase from HK$7,730.2 million as of March 31, 2020 [50]. - The Group's cash and cash equivalents increased to HK$539.3 million from HK$475.7 million as of March 31, 2020 [51]. - The total interest-bearing debts amounted to HK$1,803.9 million, slightly up from HK$1,800.8 million as of March 31, 2020 [51]. - The current ratio remained stable at 1.2, consistent with the ratio as of March 31, 2020 [52]. - The gearing ratio improved to 55.3% from 57.6% as of March 31, 2020, indicating a more conservative financial management approach [52]. Employee and Corporate Governance - As of September 30, 2020, the Group employed 1,881 employees, an increase from 1,803 employees as of March 31, 2020, with 31.2% located in Hong Kong and Macau [81]. - The Group recognizes the importance of maintaining good relationships with stakeholders to achieve long-term business growth and enhance brand competitiveness [80]. - The Company has complied with the applicable provisions of the Corporate Governance Code throughout the period for the six months ended 30 September 2020, except for a deviation regarding the chairman also serving as managing director [130]. Share Capital and Ownership - As of September 30, 2020, Mr. Tang Ching Ho holds 715,322,940 shares, representing approximately 58.08% of the Company's total issued share capital [98]. - The total issued share capital of the Company as of September 30, 2020, is 1,231,642,888 shares [113]. - Following the privatization of Easy One on October 16, 2020, Mr. Chan Chun Hong's share options were cancelled [107]. Economic and Market Conditions - The overall economic situation in Hong Kong showed signs of stabilization in the second half of 2020, following a significant downturn due to the pandemic and social conditions [81]. - The COVID-19 pandemic significantly affected market performance in early 2020, but operations returned to normal with steady and satisfactory results thereafter [38].

Financial Performance - For the financial year ended March 31, 2020, the company reported total revenue of HK$620.7 million, despite a challenging economic environment[19] - Total revenue for the fiscal year ending March 31, 2020, reached HK$620.7 million[21] - For the financial year ended 31 March 2020, total revenue decreased by 17.4% to HK$620.7 million[62] - Revenue from Chinese pharmaceutical and health food products dropped by 25.2% to HK$467.0 million, accounting for 75.2% of total revenue[65] - Revenue from Western pharmaceutical and health food products decreased by 13.5% to HK$100.3 million[62] - The Group recorded a profit attributable to owners of the parent amounting to HK$95.8 million, an increase from HK$74.6 million in 2019[63] Market Conditions - The retail sales volume in Hong Kong fell by 12.3% year-on-year in 2019, marking the largest annual decline since 1998, which impacted the company's performance[19] - Visitor arrivals to Hong Kong decreased by 14.2% year-on-year in 2019, contributing to a slump in the retail market[19] - The total retail sales value in Hong Kong fell by 31.8% year-on-year in the first two months of 2020, indicating a challenging operating environment for the retail industry[44] - The Hong Kong retail environment is expected to remain challenging in the short term due to social unrest and the COVID-19 pandemic[46] - The retail environment in Hong Kong, Macau, and mainland China is expected to face significant challenges due to ongoing social unrest, COVID-19, and the Sino-US trade war, leading to potential slower or negative economic growth[179][181] Business Strategy and Development - The company aims to revitalize its century-old brand by improving product series and Chinese medical consultation services, focusing on sustainable development[16] - The Group plans to expand its business in mainland China, including the establishment of TCM plantation bases to ensure quality[49][51] - The Group aims to enhance its professional Chinese medical services and consolidate distribution channels for long-term growth[65] - The Group plans to open new stores in community districts in Hong Kong to serve local residents, particularly targeting the elderly market for TCM products and healthcare services[45] - The Group intends to open new stores in Macao in the second half of 2020 to capitalize on the growing tourism and gaming industry[45] - The Group will continue to enhance its online retail layout in mainland China to achieve an omni-channel operation model, connecting online and offline sales[45] Product Development and Innovation - The Group launched the "Angong Sanbao" series, including "Angong Niuhuang Wan," to address cardiovascular and cerebrovascular health needs[24] - New products launched during the year include "Colla Corii Asini Powder" and "Ejiao Cake," catering to urban healthcare needs[25] - The Group aims to enhance brand loyalty for its "Pei Fu Ren" and "Pei Shi" product lines through increased marketing resources[82] - Continuous cooperation with scientific research institutes will be pursued to promote the scientific development of Chinese Medicine and enhance the distribution network[186] Retail and Distribution - The Group maintains over 55 retail stores in Hong Kong, with around 40 staffed by professional registered TCM practitioners[31] - The Group has expanded its distribution network to over 3,000 sales points in Hong Kong, ensuring comprehensive coverage of major distribution channels[33] - The Group completed the disposal of five retail shops, recognizing a total gain of HK$60.9 million during the year[37] - The group plans to relocate retail shops to more successful locations to enhance customer attraction and optimize the distribution network[70] Financial Position and Risks - As of March 31, 2020, the Group's total assets were HK$7,730.2 million, an increase of 123.1% from HK$3,454.7 million in 2019[124] - The Group's cash and cash equivalents increased to HK$475.7 million, up 178.5% from HK$171.2 million in 2019[125] - Total interest-bearing debts rose to HK$1,800.8 million, a 111.5% increase from HK$852.2 million in 2019[125] - The current ratio decreased to 1.2 from 3.5 in 2019, indicating a decline in liquidity[128] - The gearing ratio increased to 57.6% from 27.9% in 2019, reflecting higher leverage[128] - The Group faces risks including a slow growth in customer base due to a decrease in mainland tourists and the recession in Hong Kong's economy[174] - The Group has identified risks related to supply chain disruptions and cost control challenges due to rising product costs[174] Leadership and Management - Mr. Chen Zhenkang has been appointed as the Executive Director since April 1, 2018, and is responsible for managing the group's corporate affairs[198] - Ms. Tang Mui Fun has extensive experience in the pharmaceutical industry and is responsible for overall strategic planning and development for the core business[200] - The company has a strong leadership team with members holding significant positions in various committees related to pharmacy and Chinese medicine[200]